Harvard Business School Alumni Angels of Greater NY
VC Fund
New York, United States
Harvard Business School Alumni Angels of Greater NY is a VC fund in New York focused on Artificial Intelligence and Health Care. Harvard Business School Alumni Angels of Greater NY caters to early stage companies with investments and mentorship.Harvard Business School Alumni Angels of Greater NY organizes events and education programs that enable entrepreneurs to obtain insights and connect with industry leaders. It facilitates a website that enables its members andinterested parties to find information about their events, educational programs, and the company.Harvard Business School Alumni Angels of Greater NY was founded by Sean Jacobsohn in 2011. It is based in New York.
- Total investments:
- 41
- Last investment:
- Lead investor:
- 10%
Last updated:
For AI agents: llms.txt
Industries Harvard Business School Alumni Angels of Greater NY invests in
Stages Harvard Business School Alumni Angels of Greater NY invests in
Countries Harvard Business School Alumni Angels of Greater NY invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Round size
- Seed
- $570k–$3M
- Pre-Seed
- $50k–$3M
- Series A
- $2.1M–$11M
Investment Focus
Industry
- Artificial Intelligence 11 (27%)
- Health Care 8 (20%)
- SaaS 6 (15%)
- Software 6 (15%)
- FinTech 5 (12%)
Stage
- Seed 17 (41%)
- Series A 8 (20%)
- Pre-Seed 3 (7%)
- Series B 2 (5%)
- Funding Round 2 (5%)
Country
- United States 30 (73%)
- United Kingdom 2 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Lane Zimmerman
Program Manager
|
Program Manager | Total investments: 0 | Find email | |
Christian Kristin
Sector Lead
|
Sector Lead | Total investments: 0 | Find email | |
Sean Jacobsohn
Co-Founder & Co-President
|
Co-Founder & Co-President | Total investments: 29 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Stratum Biosciences
|
Stratum Biosciences is a dermatology discovery company leveraging a proprietary AI platform and over 200,000 real tissue samples to accelerate development of novel active ingredients and formulations. A resident company of Johnson and Johnson’s NYC incubator, we are solving some of skin’s toughest challenges with a pipeline of high-value IPtargeting diverse needs from skin longevity to hyperpigmentation and eczema. | $2M / Seed / Mar 27, 2026 | |
Smartlens
|
Smartlens is a clinical-stage Med Tech company with a portfolio of technologies to treat and diagnose Glaucoma - a chronic eye disease and the leading cause of irreversible blindness. The Company is running clinical trials with its novel eye pressure (IOP) monitoring contact lens (miLens) that will help improve clinical outcomes in Glaucoma. Thedisease affects hundreds of millions around the globe; even in developed countries more than 50% of the patients are currently undiagnosed, and more than 38% are going blind despite being treated. The need for monitoring eye pressure outside the clinic has been defined as an urgent need by scientific, medical, and industry leaders in ophthalmology that will help improve clinical outcomes. Smartlens’ flagship product miLens is a non-invasive and convenient way of monitoring eye pressure for anyone anywhere at any time. It will help improve early diagnosis, enable personalized treatments, and disease monitoring thus reducing the prevalence of blindness, treatment costs, and its huge burden on lives and economies. miLens is utilizing a novel, electronics-free sensor technology that is fully owned by Smartlens, Inc. and protected by its portfolio of issued and pending patents covering more than 40 countries. The Company's novel technology is also being studied at Stanford University Labs for monitoring (ICP) which is associated with certain neurological disorders, and cancers. Smartlens also owns a non-invasive drug delivery technology that monitors the IOP and releases the right medication at the right time which will help improve efficacy, patient compliance and reduce the side effects. Smartlens is the Winner of the 2021 "Outstanding Innovation in Medical Technology and Life Sciences" of High-Tech Awards by Octane. The Company has been invited to various national and international conferences, published its studies, listed among the Top 10 MedTech Startups, and featured in ABC7, Fortune, BBC, and Nature Medicine. | $5.2M / Venture - Series Unknown / Oct 14, 2025 | |
AiM Medical Robotics
|
AiM Medical Robotics developing a robotic system for use in neurosurgical procedures. The system is unique in that it is MRI compatible, allowing patients to be treated while in the MRI scanner. This gives physicians the ability to capture real-time imaging feedback to improve outcomes. Its system will help treat patients with Parkinson's,Epilepsy, Tremors, and brain cancer. | $8.1M / Series A / Sep 30, 2025 | |
Sleep.ai
|
Sleep.ai is a sleep intelligence company helping digital health, wellness, insurance, and consumer product brands improve sleep outcomes through personalized, science-backed insights. Powered by more than 1B hours of objective sleep data and over 250 scientific studies, Sleep.ai delivers APIs, SDKs, and R&D services that drive measurableimpact, from engagement and retention to health improvement and product differentiation. Its proprietary machine learning models are trained on the world’s largest validated sleep dataset, enabling actionable intelligence across every category influenced by sleep, including metabolic health, mental clarity, recovery, hormonal balance, and more. SleepScore Labs, the company’s internal R&D division, has led all 250+ studies and contributed to over 90 peer-reviewed publications, making Sleep.ai one of the most scientifically validated platforms in the space. The platform operates without requiring wearables, while remaining fully interoperable with third-party devices and health data ecosystems. | $5.5M / Aug 26, 2025 | |
Goldilock
|
Goldilock is a cybersecurity company that develops technologies for physically isolating digital systems from networks to reduce exposure to cyber threats. Its core product, FireBreak™, allows remote, non-IP-based physical disconnection of devices and infrastructure without requiring changes to existing networks or the installation of additionalsoftware or hardware. Originally created to secure cryptocurrency storage, the technology has broader applications, including operational technology protection, backup isolation, and network risk reduction. It provides implementation support and is recognized by cybersecurity and defense institutions for its approach to reducing attack surfaces through physical network control. | $2.5M / Seed / Sep 05, 2023 | |
|
Goldilock
|
Goldilock is a cybersecurity company that develops technologies for physically isolating digital systems from networks to reduce exposure to cyber threats. Its core product, FireBreak™, allows remote, non-IP-based physical disconnection of devices and infrastructure without requiring changes to existing networks or the installation of additionalsoftware or hardware. Originally created to secure cryptocurrency storage, the technology has broader applications, including operational technology protection, backup isolation, and network risk reduction. It provides implementation support and is recognized by cybersecurity and defense institutions for its approach to reducing attack surfaces through physical network control. | $1.4M / Seed / May 01, 2023 | |
Measure Studio
|
Measure Studio is an engine designed to create a social media content strategy that is informed by data. Digital publishers, companies, agencies, and influencers may consolidate and analyze their social media data using the company's engine in order to create better content. The engine offers a safe environment for managing social mediaanalytics. | Seed / Apr 21, 2023 | |
Zylö Therapeutics
|
Zylö Therapeutics offers an innovative sustained-release drug-delivery system that was developed by Joel Friedman MD PhD, Adam Friedman MD FAAD, and Andrew Draganski PhD. The delivery system uses patented hydrogel-derived nanoparticles, called Nanopods, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agentsthrough topical administration.The company was founded in 2017 and is based in Greenville, South Carolina. | $5.2M / Series B / Jun 03, 2022 | |
Futurestay
|
Futurestay is a smart way for vacation rentals to connect to everything that matters: channels, guests, payments, and their own website and brand.Futurestay has over 110,000 vacation rentals in 120 countries and is the leading independent vacation rental business solution.It uses Smart Connections to list the property on Airbnb, HomeAway, andBooking.com.It was founded in 2021 and is based in New Brunswick, New Jersey, United States. | $11M / Series A / Mar 17, 2022 | |
Uplift Labs
|
Uplift Labs specializes in helping people move better. Its AI-powered technology provides analytics to improve performance while minimizing injuries in sports, fitness, and our everyday lives. The company was founded in 2017 and is headquarters in Palo Alto, California. | $3M / Seed / Jan 25, 2022 | |
| See all 41 investments → | |||
Co-Investors
New York Angels
18 deals together
Stadia Ventures
5 deals together
Sand Hill Angels
4 deals together
Brand New Matter
3 deals together
Deepcore
3 deals together
Golden Seeds
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Harvard Business School Alumni Angels of Greater NY invest in?
Harvard Business School Alumni Angels of Greater NY invests primarily in Artificial Intelligence, Health Care and SaaS startups, most often at Seed and Series A stage. Most of the 41 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Harvard Business School Alumni Angels of Greater NY's check size?
Harvard Business School Alumni Angels of Greater NY typically joins rounds of $570k–$3M at Seed, $50k–$3M at Pre-Seed and $2.1M–$11M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Harvard Business School Alumni Angels of Greater NY participates in.
How do I contact Harvard Business School Alumni Angels of Greater NY?
Public channels for Harvard Business School Alumni Angels of Greater NY include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Harvard Business School Alumni Angels of Greater NY?
The team at Harvard Business School Alumni Angels of Greater NY includes Lane Zimmerman (Program Manager), Christian Kristin (Sector Lead) and Sean Jacobsohn (Co-Founder & Co-President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
